ZA201306402B - Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators) - Google Patents

Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)

Info

Publication number
ZA201306402B
ZA201306402B ZA2013/06402A ZA201306402A ZA201306402B ZA 201306402 B ZA201306402 B ZA 201306402B ZA 2013/06402 A ZA2013/06402 A ZA 2013/06402A ZA 201306402 A ZA201306402 A ZA 201306402A ZA 201306402 B ZA201306402 B ZA 201306402B
Authority
ZA
South Africa
Prior art keywords
azacycles
condensed
processes
preparation
crystalline forms
Prior art date
Application number
ZA2013/06402A
Other languages
English (en)
Inventor
Anthony C Blackburn
Robert M Jones
Biman B Pal
Sangdon Han
Jaimie Karyn Rueter
Anthonio Garrido Montalban
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of ZA201306402B publication Critical patent/ZA201306402B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2013/06402A 2011-02-25 2013-08-23 Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators) ZA201306402B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US201161448542P 2011-03-02 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (1)

Publication Number Publication Date
ZA201306402B true ZA201306402B (en) 2022-03-30

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/06402A ZA201306402B (en) 2011-02-25 2013-08-23 Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)

Country Status (20)

Country Link
US (4) US9458136B2 (https=)
EP (3) EP4166552B1 (https=)
JP (1) JP5945554B2 (https=)
KR (1) KR102036932B1 (https=)
CN (1) CN103608343B (https=)
AU (1) AU2012222146B2 (https=)
BR (1) BR112013021549B1 (https=)
CA (1) CA2827057C (https=)
CL (1) CL2013002436A1 (https=)
CO (1) CO6852066A2 (https=)
DK (1) DK3395812T3 (https=)
EA (1) EA035989B1 (https=)
ES (1) ES2932441T3 (https=)
IL (1) IL227782A (https=)
MX (1) MX346533B (https=)
MY (1) MY165767A (https=)
PH (1) PH12013501726A1 (https=)
SG (1) SG192817A1 (https=)
WO (1) WO2012116276A1 (https=)
ZA (1) ZA201306402B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2770866C (en) 2009-08-28 2017-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
US9458136B2 (en) * 2011-02-25 2016-10-04 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
CA3019842A1 (en) * 2016-04-10 2017-10-19 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists
EP3621619B1 (en) 2017-05-08 2023-06-28 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of visceral pain
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
TW202330496A (zh) 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
AU2002357114B2 (en) 2001-12-07 2008-07-24 Virginia Commonwealth University Treatment of neoplasia
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
JP2008505965A (ja) 2004-07-12 2008-02-28 カディラ ヘルスケア リミティド カンナビノイド受容体修飾因子としての三環式ピラゾール誘導体
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CN101238107A (zh) * 2005-06-02 2008-08-06 格兰马克药品股份有限公司 新的大麻素受体配体,含有该配体的药物组合物及其制备方法
CA2613678A1 (en) 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
PT2081572E (pt) 2006-07-04 2010-05-17 Janssen Pharmaceutica Nv Agonistas de canabinóides de benzimidazolo com um grupo heterocíclico substituído
CA2664310A1 (en) 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
WO2008053341A2 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
WO2008064054A2 (en) 2006-11-21 2008-05-29 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
US20080214537A1 (en) 2007-03-02 2008-09-04 Cara Therapeutics, Inc. Bridged phenanthridines
JP5185924B2 (ja) 2007-03-16 2013-04-17 京セラ株式会社 誘電体磁器およびコンデンサ
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
EP2170350B1 (en) 2007-06-21 2013-09-11 Cara Therapeutics, Inc. Substituted imidazoheterocycles
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
KR101787116B1 (ko) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CA2770866C (en) 2009-08-28 2017-10-10 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN103492369B (zh) * 2011-02-25 2019-03-29 艾尼纳制药公司 大麻素受体调节剂
US9458136B2 (en) * 2011-02-25 2016-10-04 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators

Also Published As

Publication number Publication date
PH12013501726A1 (en) 2014-01-13
JP5945554B2 (ja) 2016-07-05
EA035989B1 (ru) 2020-09-09
AU2012222146A1 (en) 2013-09-19
US11560369B2 (en) 2023-01-24
SG192817A1 (en) 2013-09-30
EP3395812B8 (en) 2022-11-02
US20170144993A1 (en) 2017-05-25
BR112013021549A2 (pt) 2016-11-01
US10183930B2 (en) 2019-01-22
AU2012222146B2 (en) 2017-05-11
EP3395812A1 (en) 2018-10-31
MY165767A (en) 2018-04-23
CL2013002436A1 (es) 2014-01-24
US20140135345A1 (en) 2014-05-15
CO6852066A2 (es) 2014-01-30
ES2932441T3 (es) 2023-01-19
IL227782A (en) 2017-02-28
US9458136B2 (en) 2016-10-04
US10981895B2 (en) 2021-04-20
MX346533B (es) 2017-03-14
JP2014506602A (ja) 2014-03-17
CN103608343A (zh) 2014-02-26
KR20140025353A (ko) 2014-03-04
US20190308952A1 (en) 2019-10-10
EA201391233A1 (ru) 2014-02-28
CN103608343B (zh) 2019-02-01
EP4166552B1 (en) 2025-03-19
US20210380560A1 (en) 2021-12-09
KR102036932B1 (ko) 2019-10-25
EP4166552A1 (en) 2023-04-19
BR112013021549B1 (pt) 2022-01-11
EP3395812B1 (en) 2022-09-28
NZ614787A (en) 2014-08-29
MX2013009760A (es) 2014-06-11
CA2827057C (en) 2022-06-07
DK3395812T3 (da) 2022-11-28
CA2827057A1 (en) 2012-08-30
EP2678330A1 (en) 2014-01-01
WO2012116276A1 (en) 2012-08-30
IL227782A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
ZA201306402B (en) Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
ZA201305972B (en) Method for the preparation of biphephos
LT3656758T (lt) Tarpiniai produktai, skirti c galo hsp90 inhibitoriams gaminti
SG10201501575VA (en) Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
HUE037511T2 (hu) Eljárás toluol-diamin elõállítására dinitro-toluol hidrogénezésével
SG11201400939YA (en) Process for the preparation of methoxymelonal
ZA201403736B (en) Process for the preparation of sterol derivatives
ZA201303467B (en) Method for the preparation of high-purity pharmaceutical intermediates
PL2552925T3 (pl) Sposób wytwarzania azodikarbamidów zawierających krzem
IL221184A (en) A process for preparing 1-alkylated tetrazole 5 is produced
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
HUE036284T2 (hu) Eljárás szilícium-karbid elõállítására
DK2429996T3 (en) Process for the preparation of histamine h3 receptor modulators
PT2702045T (pt) Método inovador para a preparação de etravirina
PT2390246T (pt) Processo para a preparação de aminaftona
HK1193088A (en) Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
ZA201303653B (en) Process for the preparation of gaseous synfuel
PL2598504T3 (pl) Sposób otrzymywania dimiracetamu
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
PL391682A1 (pl) Sposób otrzymywania ε-kaprolaktonu
ZA201208583B (en) Process for the preparation of hydroquinones
IL224304A (en) A process for making dichlorobulben
AU2011904710A0 (en) Device for Enhancing the Boarding of Aircraft
PL394782A1 (pl) Sposób otrzymywania zwiazków epoksydowych na katalizatorze tytanowo-silikalitowym